Physician profile
Richard Ina
NPI 1417967795
$5,575.85
in general payments reported to CMS, 2019-2025
29 companies · $1,569 in 2025
The $1,569 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $216 · 2020: $73.20 · 2021: $19.12 · 2022: $822 · 2023: $1,340 · 2024: $1,536 · 2025: $1,569.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,445.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,445.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $823.59 | 2019-2025 | |
| Novo Nordisk INC | $791.05 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $671.10 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $617.09 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $490.49 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $419.35 | 2019-2025 | Otezla, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $299.58 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $241.71 | 2020-2025 | Xifaxan |
| Abbott Laboratories | $167.64 | 2022-2025 | Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $147.05 | 2022-2025 | Nexletol |
| Exact Sciences Corporation | $127.54 | 2023-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $99.85 | 2022-2024 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $88.24 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.31 | 2024-2025 | Jardiance |
| Glaxosmithkline, LLC. | $80.80 | 2022-2025 | Shingrix, Trelegy Ellipta, Arexvy |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $76.66 | 2019-2020 | |
| Lucid Diagnostics INC. | $63.05 | 2023-2025 | |
| Amarin Pharma, INC. | $46.80 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $35.27 | 2025 | |
| Merck Sharp & Dohme LLC | $30.56 | 2025 | Capvaxive, Gardasil 9 |
| Dynavax Technologies Corporation | $26.26 | 2024 | Heplisav-B |
| Nevro Corp. | $24.73 | 2024 | Senza |
| Hologic Sales and Service, LLC | $24.57 | 2024 | Thinprep 2000 Processor, Aptima |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $19.96 | 2025 | |
| Phathom Pharmaceuticals, INC. | $17.71 | 2024 | Voquezna |
| Astellas Pharma US INC | $17.34 | 2024 | Veozah |
| Daiichi Sankyo INC. | $14.95 | 2024 | Injectafer |
| Currax Pharmaceuticals LLC | $14.51 | 2023 | Contrave |
| Novartis Pharmaceuticals Corporation | $14.09 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Ina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.